<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Nucl Med Mol Imaging</journal-id><journal-id journal-id-type="iso-abbrev">Nucl Med Mol Imaging</journal-id><journal-id journal-id-type="pmc-domain-id">2392</journal-id><journal-id journal-id-type="pmc-domain">nmmi</journal-id><journal-title-group><journal-title>Nuclear Medicine and Molecular Imaging</journal-title></journal-title-group><issn pub-type="ppub">1869-3474</issn><issn pub-type="epub">1869-3482</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7881070</article-id><article-id pub-id-type="pmcid-ver">PMC7881070.1</article-id><article-id pub-id-type="pmcaid">7881070</article-id><article-id pub-id-type="pmcaiid">7881070</article-id><article-id pub-id-type="pmid">33643485</article-id><article-id pub-id-type="doi">10.1007/s13139-020-00674-3</article-id><article-id pub-id-type="publisher-id">674</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Is There Any Need for Adjusting <sup>131</sup>I Activity for the Treatment of High Turnover Graves&#8217; Disease Compared to Normal Turnover Patients? Results from a Retrospective Cohort Study Validated by Propensity Score Analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Arora</surname><given-names initials="S">Saurabh</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Bal</surname><given-names initials="C">Chandrasekhar</given-names></name><address><email>csbal@hotmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.413618.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 1767 6103</institution-id><institution>Department of Nuclear Medicine, </institution><institution>All India Institute of Medical Sciences, </institution></institution-wrap>New Delhi, 110029 India </aff></contrib-group><pub-date pub-type="epub"><day>7</day><month>1</month><year>2021</year></pub-date><pub-date pub-type="ppub"><month>2</month><year>2021</year></pub-date><volume>55</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">375365</issue-id><fpage>15</fpage><lpage>26</lpage><history><date date-type="received"><day>12</day><month>9</month><year>2020</year></date><date date-type="rev-recd"><day>11</day><month>11</month><year>2020</year></date><date date-type="accepted"><day>16</day><month>11</month><year>2020</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>02</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>01</day><month>02</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2022-02-01 00:16:38.237"><day>01</day><month>02</month><year>2022</year></date></event></pub-history><permissions><copyright-statement>&#169; Korean Society of Nuclear Medicine 2021</copyright-statement></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="13139_2020_Article_674.pdf"/><abstract id="Abs1"><sec><title>Purpose</title><p id="Par1">To compare <sup>131</sup>I-therapy outcomes in high turnover and normal turnover Graves&#8217; disease patients and predict optimal first <sup>131</sup>I activity for high turnover patients.</p></sec><sec><title>Methods</title><p id="Par2">Retrospective cohort design (1:2) validated by propensity score analysis. Cohort 1, high turnover (2-h RAIU/24-h RAIU &#8805;&#8201;1), <italic toggle="yes">n</italic>&#8201;=&#8201;104, and cohort 2, normal turnover (ratio &lt;&#8201;1), <italic toggle="yes">n</italic>&#8201;=&#8201;208, patients were compared for post <sup>131</sup>I outcome. The cure was defined as a combined euthyroid and stable hypothyroid state following <sup>131</sup>I treatment. Logistic regression analysis was used for identifying prognostic factors. The propensity score was applied; 77 matched pairs (1:1 ratio) of high and normal turnover patients were selected as a validation set.</p></sec><sec><title>Results</title><p id="Par3">First <sup>131</sup>I cure rates of 28% in high turnover and 66% in normal turnover groups (<italic toggle="yes">p</italic>&#8201;=&#8201;0.001) were noted. The therapy cycles (median, 2 vs. 1) and cumulative <sup>131</sup>I activity (median, 15 vs. 7&#160;mCi) were required to cure hyperthyroidism in cohort 1 and cohort 2, respectively. Age (&gt;&#8201;44&#160;years), higher grade of goitre, and 2-h RAIU (&gt;&#8201;37%) were associated with <sup>131</sup>I therapy failure. The high turnover patients needed a factor of 1.5&#8211;2 times more <sup>131</sup>I activity to achieve a similar cure rate compared to the normal turnover patients. The first-dose cure rate was 31% vs. 60% by propensity score analysis (<italic toggle="yes">n</italic>&#8201;=&#8201;154), no way different (28% vs.66%) from the whole group of 312 patients.</p></sec><sec><title>Conclusion</title><p id="Par4">High turnover Graves&#8217; disease patients, if administered standard <sup>131</sup>I activity, the outcomes shall be poor. To improve the success rate, <sup>131</sup>I activity should be increased by 1.5 to 2 times in the high turnover patients.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s13139-020-00674-3.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Graves&#8217; disease</kwd><kwd>Turnover</kwd><kwd>High turnover</kwd><kwd>Normal turnover</kwd><kwd>Radioiodine therapy</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Korean Society of Nuclear Medicine 2021</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>